iSpecimen (NASDAQ:ISPC – Get Rating) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, May 10th. Individual interested in listening to the company’s earnings conference call can do so using this link.
Shares of ISPC stock traded up $0.12 during trading on Tuesday, reaching $3.35. The company had a trading volume of 1,000 shares, compared to its average volume of 523,454. The stock has a 50 day moving average price of $3.94. iSpecimen has a one year low of $3.06 and a one year high of $28.98. The company has a debt-to-equity ratio of 0.11, a quick ratio of 13.15 and a current ratio of 13.15.
Hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new position in shares of iSpecimen in the third quarter worth about $74,000. Geode Capital Management LLC acquired a new position in shares of iSpecimen during the 4th quarter worth about $103,000. Finally, Millennium Management LLC acquired a new position in shares of iSpecimen during the 3rd quarter worth about $162,000. Institutional investors own 28.26% of the company’s stock.
About iSpecimen (Get Rating)
iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.
Featured Stories
- Get a free copy of the StockNews.com research report on iSpecimen (ISPC)
- Another Buy The Dip Opportunity In Freshpet
- Inflation Wreaks Havoc On Haverty Furniture Company
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- GitLab Stock is Trying to Put in a Bottom Here
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.